Home › Funds › Soleus Capital Management, L.P. › ERAS

Soleus Capital Management, L.P. position in ERAS

ERASCA INC · Health Care

Soleus Capital Management, L.P. reported holding 5,112,000 shares of ERAS (ERASCA INC) in its Q3 2026 13F filing — a position valued at US$74.9M, representing 2.66% of its reported portfolio and ranking #9 among its reported holdings. Soleus Capital Management, L.P. has disclosed ERAS holdings in 9 of the last 10 reported quarters, going back to Q2 2024.

Latest position (Q3 2026)5.11M sh
Reported value held$74.94M
Portfolio Weight2.66%
First reportedQ2 2024
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Soleus Capital Management, L.P.'s ERAS position evolved

Soleus Capital Management, L.P. first disclosed a stake in ERAS in Q2 2024 at 2,162,162 shares (US$5.1M). The position peaked in Q3 2026 at 5,112,000 shares, worth US$74.9M. Across 9 filings, Soleus Capital Management, L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 5,112,000 shares valued at US$74.9M — an increase of 2,412,000 shares quarter over quarter.. Notable position changes include a 89% increase in Q3 2026 (shares rose 3% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 2.16M $5.10M New
Q3 2024 2.16M $5.90M Hold
Q4 2024 2.16M $5.43M Hold
Q1 2025 2.16M $2.96M Hold
Q2 2025 2.16M $2.75M Hold
Q3 2025 2.16M $4.71M Hold
Q4 2025 2.16M $8.04M Hold
Q2 2026 2.70M $49.46M New
Q3 2026 5.11M $74.94M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ERAS and 13F data

ERAS (ERASCA INC) is a Health Care company. 63 other funds we track also report a position in ERAS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$432.1M), RTW INVESTMENTS, LP (US$329.1M), Venrock Adviser, LLC (US$294.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ERAS

All ERAS fund holders →

FAQ

How long has Soleus Capital Management, L.P. held ERAS?

Soleus Capital Management, L.P. has disclosed ERAS holdings in 9 of the last 10 reported quarters, going back to Q2 2024.

What is Soleus Capital Management, L.P.'s current position in ERAS?

As of Q3 2026, Soleus Capital Management, L.P. holds 5.11M shares of ERAS (ERASCA INC), valued at $74.94M, representing 2.66% of its reported portfolio and ranking #9.

Has Soleus Capital Management, L.P. been buying or selling ERAS?

In the latest 13F filing (Q3 2026), Soleus Capital Management, L.P. increased its position in ERAS. The position peaked in Q3 2026 at 5.11M shares.

Which other funds hold ERAS?

Other major institutional holders of ERAS include Frazier Life Sciences Management, L.P., RTW INVESTMENTS, LP, Venrock Adviser, LLC, among 63 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.